Kodiak Sciences (KOD) closed at $98.51 on November 4, 2026, down 0.4% from the previous close, on volume of 971,310 shares (30-day average 2,839,487).
Data as of November 4, 2026.
4-Nov-2026
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
PRNewswire (Wed, 7-Oct 7:00 AM ET)
4 Explosive Stories Enter the Investor Spotlight
Globe Newswire (Mon, 28-Sep 11:51 AM ET)
Market Chameleon (Mon, 28-Sep 5:52 AM ET)
PRNewswire (Fri, 25-Sep 6:02 PM ET)
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results
PRNewswire (Thu, 13-Aug 4:00 PM ET)
PRNewswire (Mon, 10-Aug 4:44 PM ET)
PRNewswire (Thu, 6-Aug 7:00 AM ET)
Market Chameleon (Wed, 1-Apr 5:47 AM ET)
Market Chameleon (Fri, 27-Mar 6:30 AM ET)
Kodiak Sciences Inc has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) platform, for retinal medicines. Its investigational medicine, tarcocimab tedromer (Zenkuda or tarcocimab), is an anti-VEGF therapy built on Kodiak's proprietary ABC platform. Another investigational medicine, KSI-501, is an anti-interleukin 6, or IL-6, VEGF-trap bispecific therapy built on the ABC platform and is being developed for high-prevalence retinal vascular diseases and intended to address the unmet needs of extended durability and targeting disease biology beyond VEGF for differentiated efficacy. Its third investigational medicine, KSI-101, is a high-strength (100 mg/mL) bispecific protein targeting IL-6 and VEGF.
Kodiak Sciences trades on the NASDAQ stock market under the symbol KOD.
As of November 4, 2026, KOD stock price declined to $98.51 with 971,310 million shares trading.
KOD has a beta of 1.02, meaning it tends to be more sensitive to market movements. KOD has a correlation of 0.01 to the broad based SPY ETF.
KOD has a market cap of $6.19 billion. This is considered a Mid Cap stock.
In the last 3 years, KOD traded as high as $104.00 and as low as $1.59.
The top ETF exchange traded funds that KOD belongs to (by Net Assets): XBI, VTI, IWM, IBB, VXF.
KOD has outperformed the market in the last year with a price return of +430.8% while the SPY ETF gained +13.3%. KOD has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +147.3% and +6.0%, respectively, while the SPY returned +1.5% and -0.3%, respectively.
KOD support price is $94.02 and resistance is $103.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KOD shares will trade within this expected range on the day.
